BACKGROUND: In July, 1999, a single dose of live-attenuated SA 14-14-2 Japanese encephalitis vaccine was given to children aged 1-15 years in the Terai region of Nepal. Cases of natural infection occurred almost immediately. Our aim was to assess the long-term protective effect of this vaccination. METHODS: In 2000, this same population had a second seasonal exposure to the virus. We therefore did a case-control study to measure the prevalence of vaccination against Japanese encephalitis in 35 patients hospitalised for the disease 1 year after immunisation, and in age-sex matched village controls. FINDINGS: Of 35 children resident in Bardiya and Banke districts admitted to the Bheri Zonal Hospital with serologically confirmed Japanese encephalitis, only one had been vaccinated in 1999. In 430 age-sex matched village controls, 234 (54.4%) were vaccinated. We calculated a median unbiased estimate of the odds ratio of 0.0155, with lower and upper confidence limits of 0.0004 and 0.0986. The protective effect of vaccine after 12-15 months was 98.5% (CI 90.1-99.2%). INTERPRETATION: Our study provides evidence of sustained high protection afforded by one dose of live attenuated SA 14-14-2 vaccine in Nepalese children.
BACKGROUND: In July, 1999, a single dose of live-attenuated SA 14-14-2Japanese encephalitis vaccine was given to children aged 1-15 years in the Terai region of Nepal. Cases of natural infection occurred almost immediately. Our aim was to assess the long-term protective effect of this vaccination. METHODS: In 2000, this same population had a second seasonal exposure to the virus. We therefore did a case-control study to measure the prevalence of vaccination against Japanese encephalitis in 35 patients hospitalised for the disease 1 year after immunisation, and in age-sex matched village controls. FINDINGS: Of 35 children resident in Bardiya and Banke districts admitted to the Bheri Zonal Hospital with serologically confirmed Japanese encephalitis, only one had been vaccinated in 1999. In 430 age-sex matched village controls, 234 (54.4%) were vaccinated. We calculated a median unbiased estimate of the odds ratio of 0.0155, with lower and upper confidence limits of 0.0004 and 0.0986. The protective effect of vaccine after 12-15 months was 98.5% (CI 90.1-99.2%). INTERPRETATION: Our study provides evidence of sustained high protection afforded by one dose of live attenuated SA 14-14-2 vaccine in Nepalese children.
Authors: Gregory D Gromowski; Cai-Yen Firestone; José Bustos-Arriaga; Stephen S Whitehead Journal: Am J Trop Med Hyg Date: 2014-10-13 Impact factor: 2.345
Authors: Shyam P Dumre; Geeta Shakya; Kesara Na-Bangchang; Veerachai Eursitthichai; Hans Rudi Grams; Senendra R Upreti; Prakash Ghimire; Khagendra KC; Ananda Nisalak; Robert V Gibbons; Stefan Fernandez Journal: Am J Trop Med Hyg Date: 2013-02-18 Impact factor: 2.345
Authors: S Pakakasama; S Wattanatitan; C Techasaensiri; S Yoksan; S Sirireung; S Hongeng Journal: Bone Marrow Transplant Date: 2014-07-21 Impact factor: 5.483